Skip to main content

Select Drug Profiles

Practice Management

Increased Burden of Healthcare Utilization and Cost Associated with Opioid-Related Constipation Among Patients with Noncancer Pain

Ancilla W. Fernandes, PhD, David M. Kern, PhD, Catherine Datto, MD, MS, Yen-Wen Chen, PhD, Charles McLeskey, MD, Ozgur Tunceli, PhD

Stakeholder Perspective

Can Improved Management of Opioid-Induced Constipation Mitigate the Associated Costs?

by Gary M. Owens, MD

Conference Highlights AMCP

Implications of Real-World Data and Pharmacoeconomics for Managed Care

Lilly Ostrovsky

Practice Management

Will the PCSK9 Inhibitors Be Employers’ “Line in the Sand”?

Stanton R. Mehr

In the News, Lung Cancer, Oncology

New Data Show Osimertinib Effective as First-Line Treatment of NSCLC with EGFR Mutation

Lilly Ostrovsky

Lilly Ostrovsky

Atezolizumab First PD-L1 Inhibitor Approved by the FDA for Advanced or Metastatic Urothelial Cancer

Lilly Ostrovsky

Yondelis (Trabectedin) Approved for the Treatment of Unresectable or Metastatic Soft-Tissue Sarcomas

Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder

Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Lisa A. Raedler, PhD, RPh

Tagrisso (Osimertinib) Approved for Patients with Non–Small-Cell Lung Cancer and the EGFR T790M Mutation

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

ProAir RespiClick (Albuterol Sulfate): First Breath-Actuated Inhaler Approved for the Treatment or Prevention of Bronchospasm

Lisa A. Raedler, PhD, RPh

Page 111 of 244
Results 1101 - 1110 of 2434